Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCRNASDAQ:INDVNASDAQ:SDGRNASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCRImmunocore$37.25-2.0%$30.23$23.15▼$43.12$1.87B0.83372,294 shs549,586 shsINDVIndivior$14.07+3.5%$10.86$7.33▼$17.09$1.94B0.661.08 million shs1.87 million shsSDGRSchrödinger$24.62+3.3%$23.05$16.60▼$28.47$1.81B1.84874,681 shs1.17 million shsUPXIUpexi$11.21-6.0%$8.53$1.90▼$22.57$425.03M-0.3869,159 shs309,756 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCRImmunocore-2.03%+2.08%+24.50%+25.00%-13.47%INDVIndivior+3.53%+10.61%+22.40%+45.05%-21.00%SDGRSchrödinger+3.27%+13.82%+3.77%+17.13%+4.90%UPXIUpexi-5.96%+12.44%-2.44%+309.12%+10.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMCRImmunocore2.9219 of 5 stars4.30.00.00.03.24.20.0INDVIndivior1.7355 of 5 stars1.63.00.00.02.61.71.9SDGRSchrödinger2.4189 of 5 stars3.51.00.00.03.02.50.6UPXIUpexi1.5898 of 5 stars0.05.00.00.02.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCRImmunocore 2.55Moderate Buy$58.8958.09% UpsideINDVIndivior 3.25Buy$15.006.61% UpsideSDGRSchrödinger 3.00Buy$32.8033.23% UpsideUPXIUpexi 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest UPXI, SDGR, IMCR, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.005/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.004/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.004/7/2025IMCRImmunocoreMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.003/12/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.003/12/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.003/7/2025IMCRImmunocoreMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight$35.00 ➝ $35.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCRImmunocore$333.58M5.61N/AN/A$7.42 per share5.02INDVIndivior$1.17B1.66$2.85 per share4.94N/A∞SDGRSchrödinger$230.49M7.84$0.66 per share37.42$7.60 per share3.24UPXIUpexi$16.56M25.66N/AN/A$2.85 per share3.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCRImmunocore-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%8/6/2025 (Estimated)INDVIndivior$2M-$0.31N/A8.23N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)SDGRSchrödinger$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/AN/AN/AN/A7/8/2025 (Estimated)Latest UPXI, SDGR, IMCR, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/7/2025Q1 2025SDGRSchrödinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCRImmunocoreN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCRImmunocore1.033.783.76INDVIndiviorN/A0.830.65SDGRSchrödingerN/A4.114.11UPXIUpexi0.350.580.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCRImmunocore84.50%INDVIndivior60.33%SDGRSchrödinger79.05%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipIMCRImmunocore10.40%INDVIndiviorN/ASDGRSchrödinger8.60%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCRImmunocore32050.23 million45.48 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableSDGRSchrödinger79073.38 million66.59 millionOptionableUPXIUpexi13037.92 million863,000OptionableUPXI, SDGR, IMCR, and INDV HeadlinesRecent News About These CompaniesUpexi options begin trading on Nasdaq marketJune 6 at 7:57 PM | investing.comUpexi Approved for Options Trading on NasdaqJune 5 at 9:00 AM | globenewswire.comWall Street Zen Upgrades Upexi (NASDAQ:UPXI) to HoldJune 2, 2025 | marketbeat.comUpexi (NASDAQ:UPXI) Raised to Hold at Wall Street ZenJune 1, 2025 | americanbankingnews.comUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateMay 31, 2025 | marketbeat.comUpexi, Inc. (NASDAQ:UPXI) Sees Significant Drop in Short InterestMay 31, 2025 | americanbankingnews.comUpexi to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25May 30, 2025 | globenewswire.comUpexi releases presentation detailing Solana treasury strategyMay 29, 2025 | finance.yahoo.comUpexi Partners with Crypto-Native Marketing and Design Firm, GMI Digital, to Drive Solana-Focused StrategyMay 29, 2025 | globenewswire.comUpexi, Inc. Acquires 77,879 Locked SOL for $11.8 Million, Increasing Holdings to 679,677 SOLMay 28, 2025 | quiverquant.comUpexi, Inc. Buys Additional Locked SOL at a Discount for $11.8 millionMay 28, 2025 | taiwannews.com.twUpexi, Inc. Buys Additional Locked SOL at a Discount for $11.8 millionMay 28, 2025 | globenewswire.comUpexi Releases Investor Presentation Detailing Solana Treasury StrategyMay 27, 2025 | accessnewswire.comUpexi Inc.May 26, 2025 | wsj.comUpexi Appoints Brian Rudick, CFA as Chief Strategy OfficerMay 22, 2025 | accessnewswire.comUpexi Reports First Quarter 2025 Financial Results and Provides Update on Solana Treasury StrategyMay 16, 2025 | accessnewswire.comUpexi Buys Discounted Locked SOL, Surpasses $100 Million of SOL and Becomes the Largest Publicly-Traded Solana Treasury CompanyMay 12, 2025 | finanznachrichten.deUpexi Increases Solana Treasury to 201,500 Solana Tokens for $30 Million and Begins to Generate Staking RevenueMay 6, 2025 | finanznachrichten.deClassover Bets On Solana To Reshape Its Balance Sheet, Financial Strategy – Stock Continues Rally With 70% Pre-Market JumpMay 2, 2025 | msn.comThis is Why Companies are Diversifying with Cryptocurrencies, Like BitcoinApril 30, 2025 | baystreet.caCORRECTION FROM SOURCE: Upexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana StrategyApril 29, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPXI, SDGR, IMCR, and INDV Company DescriptionsImmunocore NASDAQ:IMCR$37.25 -0.77 (-2.03%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$37.26 +0.02 (+0.04%) As of 06/6/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Indivior NASDAQ:INDV$14.07 +0.48 (+3.53%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$14.06 -0.01 (-0.07%) As of 06/6/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Schrödinger NASDAQ:SDGR$24.62 +0.78 (+3.27%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$24.49 -0.13 (-0.53%) As of 06/6/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Upexi NASDAQ:UPXI$11.21 -0.71 (-5.96%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$11.20 -0.02 (-0.13%) As of 06/6/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
